A phase I clinical trial to evaluate the safety and immunogenicity of PENNVAX-B (gag, pol, env) given alone, with IL-12 DNA, or with a dose escalation of IL-15 DNA, in healthy, HIV-1-uninfected adults participants.

Trial Profile

A phase I clinical trial to evaluate the safety and immunogenicity of PENNVAX-B (gag, pol, env) given alone, with IL-12 DNA, or with a dose escalation of IL-15 DNA, in healthy, HIV-1-uninfected adults participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2013

At a glance

  • Drugs HIV clade B DNA vaccine Inovio (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2013 Results of this trial and one other phase I trial (HVTN080) published in the Journal of Infectious Diseases according to an Inovio media release.
    • 29 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top